跳至主要内容
临床试验/NCT00316212
NCT00316212终止2 期

Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel Group Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Graft Surgery Involving Cardiopulmonary Bypass

Merck Sharp & Dohme LLC27 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2006年4月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
160
试验地点
27
主要终点
Postoperative chest drainage volume

研究概览

简要总结

The purpose of this trial is to identify a dose or doses of INS50589 intravenous infusion that are well-tolerated and which reduce postoperative bleeding and blood product transfusion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Are scheduled for primary CABG by median sternotomy involving cardiopulmonary bypass
  • •Willing to receive allogeneic blood product transfusions during and after surgery

排除标准

  • •Have had previous cardiac surgery
  • •Have had previous median sternotomy
  • •Have tendency for bleeding or family history of bleeding
  • •Have an abnormally low platelet count
  • •Have received certain anticoagulant or antiplatelet medications within a specified time period prior to the scheduled CABG surgery

结局指标

主要结局

Postoperative chest drainage volume

次要结局

  • Requirement for perioperative blood product transfusion
  • Incidence of complications after surgery

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (27)

Loading locations...

相似试验